文献速递慢性肾脏病

肾小管损伤尿液生物标志物未能改善慢性肾脏病进展的临床预测模型

Urine biomarkers of tubular injury do not improve on the clinical model predicting chronic kidney disease progression.
PubMed 文献 · Kidney Int · 2016-10-28

在前瞻性慢性肾功能不全队列研究的2466名参与者中,于高度标准化条件下检测尿肾损伤分子-1、中性粒细胞明胶酶相关脂质运载蛋白、N-乙酰-β-D-氨基葡萄糖苷酶和肝型脂肪酸结合蛋白。随访9433人年期间发生581例慢性肾脏病进展。未校正时尿液损伤生物标志物与进展强关联,但校正基于血清肌酐的估算肾小球滤过率和尿白蛋白/肌酐比值后,无一独立关联,也未改善基础临床模型的高C统计量(0.89)。

要点

  • 未校正时尿肾小管损伤生物标志物最高与最低五分位比较的风险比在7至15之间。
  • 校正估算肾小球滤过率和尿白蛋白/肌酐比值后,无一生物标志物独立关联慢性肾脏病进展。
  • 加入肾小管损伤生物标志物未改善基础临床模型的高C统计量(0.89)。

核心结论

  • 在慢性肾脏病患者中,包含基于血清肌酐的估算肾小球滤过率和尿白蛋白/肌酐比值的临床模型进行风险预测时,加入肾小管损伤生物标志物并未改善预测。

研究设计与样本

  • 前瞻性慢性肾功能不全队列研究,纳入2466名参与者,在高度标准化条件下检测尿肾损伤分子-1、中性粒细胞明胶酶相关脂质运载蛋白、N-乙酰-β-D-氨基葡萄糖苷酶和肝型脂肪酸结合蛋白。

主要发现

  • 随访9433人年期间,共发生581例慢性肾脏病进展,定义为新发终末期肾病或估算肾小球滤过率减半。
  • 未校正Cox比例风险模型中,经尿肌酐标准化的尿液损伤生物标志物最高与最低五分位比较的风险比在7至15之间,与慢性肾脏病进展强关联。
  • 校正基于血清肌酐的估算肾小球滤过率和尿白蛋白/肌酐比值后,无一标准化生物标志物独立关联慢性肾脏病进展。
  • 无一生物标志物改善基础临床模型的高C统计量(0.89)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Few investigations have evaluated the incremental usefulness of tubular injury biomarkers for improved prediction of chronic kidney disease (CKD) progression. As such, we measured urinary kidney injury molecule-1, neutrophil gelatinase-associated lipocalin, N-acetyl-ß-D-glucosaminidase and liver fatty acid binding protein under highly standardized conditions among 2466 enrollees of the prospective Chronic Renal Insufficiency Cohort Study. During 9433 person-years of follow-up, there were 581 cases of CKD progression defined as incident end-stage renal disease or halving of the estimated glomerular filtration rate. Levels of the urine injury biomarkers, normalized for urine creatinine, were strongly associated with CKD progression in unadjusted Cox proportional hazard models with hazard ratios in the range of 7 to 15 comparing the highest with the lowest quintiles. However, after controlling for the serum creatinine-based estimated glomerular filtration rate and urinary albumin/creatinine ratio, none of the normalized biomarkers was independently associated with CKD progression. None of the biomarkers improved on the high (0.89) C-statistic for the base clinical model. Thus, among patients with CKD, risk prediction with a clinical model that includes the serum creatinine-based estimated glomerular filtration rate and the urinary albumin/creatinine ratio is not improved on with the addition of renal tubular injury biomarkers.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Hsu CY, Xie D, Waikar SS, et al. Urine biomarkers of tubular injury do not improve on the clinical model predicting chronic kidney disease progression. Kidney Int. 2016. PMID: 28029431. doi:10.1016/j.kint.2016.09.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。